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ARTICLE
Identiﬁcation of ADAR1 adenosine deaminase
dependency in a subset of cancer cells
Hugh S. Gannon1,2, Tao Zou1,2, Michael K. Kiessling3,4, Galen F. Gao 2, Diana Cai1,2, Peter S. Choi1,2,
Alexandru P. Ivan 1, Ilana Buchumenski5, Ashton C. Berger2, Jonathan T. Goldstein2,
Andrew D. Cherniack 1,2, Francisca Vazquez 2, Aviad Tsherniak 2, Erez Y. Levanon 5,
William C. Hahn 1,2,6,7 & Matthew Meyerson 1,2,7,8
Systematic exploration of cancer cell vulnerabilities can inform the development of novel
cancer therapeutics. Here, through analysis of genome-scale loss-of-function datasets, we
identify adenosine deaminase acting on RNA (ADAR or ADAR1) as an essential gene for the
survival of a subset of cancer cell lines. ADAR1-dependent cell lines display increased
expression of interferon-stimulated genes. Activation of type I interferon signaling in the
context of ADAR1 deﬁciency can induce cell lethality in non-ADAR1-dependent cell lines.
ADAR deletion causes activation of the double-stranded RNA sensor, protein kinase R (PKR).
Disruption of PKR signaling, through inactivation of PKR or overexpression of either a wild-
type or catalytically inactive mutant version of the p150 isoform of ADAR1, partially rescues
cell lethality after ADAR1 loss, suggesting that both catalytic and non-enzymatic functions of
ADAR1 may contribute to preventing PKR-mediated cell lethality. Together, these data
nominate ADAR1 as a potential therapeutic target in a subset of cancers.
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Despite the discovery and widespread use of novel targetedtherapies that inhibit the activity of mutant oncogeneproducts, such as EGFR and ALK1,2, and immu-
notherapies that modulate anti-tumor immunity3–6, lung cancer
remains the leading cause of cancer death worldwide. Impor-
tantly, most lung cancer patients are not eligible for targeted
therapies because their tumors lack a targetable genomic altera-
tion. Moreover, a substantial proportion of lung cancer patients
treated with immune checkpoint inhibitors do not achieve an
objective response4–6. Thus, the discovery of novel therapeutic
modalities remains critical to improving outcomes in lung cancer
care.
Lung cancer cells may harbor speciﬁc genomic or functional
alterations that render them vulnerable to particular genetic
perturbations7,8. Identiﬁcation of these synthetic lethal interac-
tions may offer an opportunity for the development of novel
classes of therapies for lung cancer. In this study, we utilize
genome-scale loss-of-function datasets to uncover genetic
dependencies in lung cancer cell lines. We ﬁnd that lung cancer
cell lines expressing high levels of interferon-stimulated genes
(ISGs) are vulnerable to deletion of the RNA adenosine deami-
nase, ADAR or ADAR1. ADAR deletion induces phosphorylation
of the cytoplasmic double-stranded RNA (dsRNA) sensor PKR,
leading to downstream signaling. Deletion of PKR can partially
rescue cell lethality after ADAR1 loss, indicating that ADAR
genetic dependency is at least partly mediated by PKR signaling.
Overexpression studies demonstrate that both the catalytic and
non-enzymatic functions of ADAR1 may restrain PKR-mediated
a
c
e
g
d
f
b
4
2
0
150
100
50
GFP sg2
GFP sg2sgRNA #1
sgRNA #2
HCC366
Crystal violetGFP sg2 ADAR sg1
HCC366
ADAR sg2
IFNAR1 sg1
IFNAR1 sg2
IFNAR1 sg1 IFNAR1 sg2
0
150
100
50
0
100
50
0
Vehicle Interferon-α Interferon-βNCI-H1437 HCC1438 SW900 NCI-H596
0 20
NCI-H1650
NCI-H196
HCC366
40
ADAR KO
insensitive
ADAR KO
insensitive
ADAR1 p150p110
NC
I-H
12
99
A5
49
HC
C3
66
NC
I-H
16
50
NC
I-H
19
6
HC
C1
43
8
SW
90
0
PA
TU
-8
90
2
NC
I-H
59
6
MDA5
150
MW
(kDa)
100
150
75
A549
*
*
37
Total PKR
β-Actin
ADAR KO
sensitive
ADAR KO
sensitive
Lung cancer cell lines
AD
AR
 k
no
ck
do
wn
de
pe
nd
en
cy
 (z
-
sc
o
re
)
60 80 100 120
150
%
 c
el
l v
ia
bi
lity
 re
la
tiv
e
to
 G
FP
 c
on
tro
l
%
 c
el
l v
ia
bi
lity
 re
la
tiv
e
to
 G
FP
 c
on
tro
l
%
 c
el
l v
ia
bi
lity
 re
la
tiv
e
to
 G
FP
 c
on
tro
l
%
 c
el
l v
ia
bi
lity
 re
la
tiv
e
to
 G
FP
 c
on
tro
l
ns
** *** *
100
50
0
100
Lo
g 
IF
N-
β (
pg
/m
l)
10
1
0.1 A549
NCI-H1437
NCI-H1299
HCC366
NCI-H1650
NCI-H196
NCI-H596
SW
900
HCC1438
PATU-8902
A549 HCC366 NCI-H1650 NCI-H196
GFP sg1
GFP sg2
ADAR sg2
ADAR sg1
GFP sg1
GFP sg2
Non-targeting
ADAR sg2
ADAR sg1
GFP sg2
ADAR sg2
ADAR sg1
GFP sg1
ADAR sg2
ADAR sg1
–2
–4
–6
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07824-4
2 NATURE COMMUNICATIONS |          (2018) 9:5450 | https://doi.org/10.1038/s41467-018-07824-4 | www.nature.com/naturecommunications
cell lethality in ADAR1-dependent lung cancer cell lines. Taken
together, our data suggest that ADAR1 may represent a potential
therapeutic target in cancers displaying activation of interferon
response pathways.
Results
ADAR1 dependency in cancer cell lines with elevated ISGs. We
analyzed publicly available, genome-scale shRNA screen-
ing datasets9 in search of novel genetic dependencies in lung
cancer. Based on previously described criteria9, we identiﬁed 11
genes that are potentially required for the survival of subsets of
lung cancer cell lines (Supplementary Table 1). These genes
included SMARCA2 and PRKDC7,8, which have been shown to be
synthetic lethal targets in subsets of lung cancers, as well as the
adenosine deaminase acting on RNA gene, ADAR. Suppression of
ADAR gene expression showed outlier lethality in HCC366, NCI-
H196, and NCI-H1650 lung cancer cells compared to other tested
lung cancer cell lines (Fig. 1a). CRISPR-Cas9-mediated gene
knockout (KO) provided orthogonal evidence for ADAR depen-
dency in these cell lines (Fig. 1b). In contrast, ADAR deletion did
not induce signiﬁcant cell lethality in ADAR KO-insensitive A549
cells (Fig. 1b and Supplementary Fig. 1a).
ADAR encodes multiple isoforms of the ADAR1 protein,
including a constitutively expressed, predominantly nuclear p110
isoform and an interferon-inducible, nuclear and cytoplasmic
p150 isoform10,11. ADAR1 edits adenosine (A) to inosine (I) in
RNA. This editing function is thought to destabilize regions of
RNA duplexes that are formed by inverted repetitive elements
within RNAs10–15. In this manner, A-to-I editing has been
proposed to prevent cytoplasmic RNA sensors of the innate
immune system, such as MDA5 and PKR, from erroneously
recognizing endogenous dsRNA as foreign11–15. Indeed, germline
mutations in human ADAR cause Aicardi-Goutières syndrome,
which is characterized by constitutive activation of type I
interferon (IFN-I) signaling and widespread autoinﬂammation16,
highlighting the role of ADAR1 in curbing aberrant IFN-I
responses.
To investigate the importance of the IFN-I pathway in
ADAR1-dependent lung cancer cell lines, we performed differ-
ential gene expression analysis on publicly available RNA
sequencing (RNA-seq) data derived from cancer cell lines in
the Cancer Cell Line Encyclopedia (CCLE)17. Consistent with the
known role of ADAR1 in IFN-I signaling, we found higher
expression of ISGs in ADAR1-dependent versus non-ADAR1-
dependent lung cancer cell lines (Supplementary Data 1),
suggesting that an elevated interferon gene expression signature
may serve as a biomarker for ADAR1 dependency. Next, we
identiﬁed additional lung cancer cell lines with elevated interferon
gene expression signatures, none of which had been analyzed in
published shRNA or CRISPR-Cas9 loss-of-function screens
(Supplementary Data 2). Similar to the ADAR1-dependent cell
lines identiﬁed in the genome-scale shRNA screening datasets,
these cell lines (NCI-H596, HCC1438, and SW900) also
expressed high levels of interferon-inducible proteins, such as
PKR and MDA5 (Fig. 1c), secreted IFN-β spontaneously (Fig. 1d),
and were sensitive to ADAR1 loss (Fig. 1e). Of note, this pattern
of ADAR1 dependency was not restricted to lung cancer cell lines.
Analysis of a CRISPR-Cas9 screen18 identiﬁed an ADAR1-
dependent pancreatic cancer cell line, PATU-8902, which also
expressed high levels of interferon-inducible proteins (Fig. 1c, d
and Supplementary Fig. 1b).
Next, we sought to determine whether activation of IFN-I
signaling in the context of ADAR1 deﬁciency could induce cell
lethality in non-ADAR1-dependent cancer cell lines. We deleted
ADAR in A549 and NCI-H1437 cells, which normally tolerate
ADAR1 deﬁciency, and then treated these cell lines with IFN-I.
Treatment with either interferon-α (IFN-α) or interferon-β (IFN-
β) caused increased cell lethality in ADAR1-deﬁcient A549 and
NCI-H1437 cells as compared to vehicle-treated controls (Fig. 1f
and Supplementary Fig. 1c). We observed similar results in an
extended panel of ADAR KO-insensitive cancer cell lines treated
with IFN-β, although the magnitude of the cell lethality
phenotype varied between cell lines (Supplementary Fig. 1d).
ADAR1-deﬁcient A549 cells treated with IFN-β showed increased
caspase 3/caspase 7 activity, indicative of increased apoptosis
(Supplementary Fig. 1e). These data demonstrate that activation
of IFN-I signaling in the setting of ADAR1 deﬁciency can induce
cell lethality in normally ADAR KO-insensitive cancer cell lines.
To establish whether IFN-I signaling is required for ADAR1
dependency, we deleted a component of the IFN-I receptor,
IFNAR1, in ADAR1-dependent cell lines prior to ADAR knock-
out. We conﬁrmed that IFNAR1 deletion decreased IFN-I signal
transduction as shown by decreased STAT1 phosphorylation and
decreased upregulation of the ISGs MDA5 and ISG15 in response
to exogenous IFN-β stimulation (Supplementary Fig. 2a). IFNAR1
knockout did not substantially rescue cell lethality induced by
ADAR deletion in either HCC366 or NCI-H1650 cells (Fig. 1g
and Supplementary Fig. 2b, c), suggesting that IFN-I signaling is
not necessary for the cell lethality caused by ADAR deletion in
these cell lines. Therefore, an elevated interferon gene expression
signature appears to be a biomarker for vulnerability to ADAR1
loss.
Fig. 1 High expression of ISGs in cancer cell lines is predictive of sensitivity to ADAR deletion. a Z-scores representing the degree of cell lethality after ADAR
knockdown in lung cancer cell lines included in published genome-scale loss-of-function screens9. Z-scores represent the number of standard deviations
from the mean for each data point. b Cell viability was assessed by ATP bioluminescence 11 days after GFP or ADAR KO with CRISPR-Cas9. ATP
bioluminescence values were normalized to the GFP sg1 control within each cell line. Three independent biological replicates were performed for each cell
line. *p= 0.0054, **p= 0.0008, and ***p < 0.0001 as calculated by the Kruskal–Wallis test. c Immunoblots showing protein levels of ISGs and β-actin
(loading control) in ADAR KO-sensitive and KO-insensitive cancer cell lines (n= 3). d Spontaneous IFN-β secretion by ADAR KO-sensitive and KO-
insensitive cancer cell lines as measured by ELISA 24 h after replacement of culture media. Technical replicates from one representative experiment are
shown (n= 2). e Cell viability was assessed by ATP bioluminescence 11 days after GFP or ADAR KO with CRISPR-Cas9 in additional lung cancer cell lines.
ATP bioluminescence values were normalized to the GFP sg1 control within each cell line (n= 1). f Cell viability of control or ADAR1-deﬁcient A549 cells
was assessed by ATP bioluminescence 3 days after vehicle or IFN-I treatment (10 ng/mL). ATP bioluminescence values were normalized to the GFP sg1
control within each treatment group. Three independent biological replicates were performed. Two-way ANOVA showed a signiﬁcant interaction between
ADAR KO and IFN-I treatment (*p < 0.0001, degrees of freedom= 8, F-ratio= 10.51). Dunnett’s multiple comparisons post-test showed a signiﬁcant
difference between vehicle and IFN-I treatment groups and between control and ADAR KO groups (*p < 0.0001). g Cell viability of control or IFNAR1-
deﬁcient HCC366 cells was assessed by crystal violet staining 11–13 days after GFP or ADAR KO with CRISPR-Cas9. A representative image of crystal violet
staining (left) and quantitation of cell viability (right) from two independent biological replicates are shown. Cell viability values were normalized to the GFP
sg2 control #2 within each group of isogenic cells. Error bars represent standard deviation in all graphs
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ADAR1 dependency does not require MDA5/MAVS signaling.
To determine the mechanism of cell lethality after ADAR dele-
tion, we examined whether innate immune sensing pathways
known to act downstream of ADAR1 were necessary for ADAR1
dependency. Prior studies have demonstrated that
ADAR1 suppresses the activation of the cytoplasmic dsRNA
sensor MDA5, which signals to MAVS to upregulate expression
of ISGs in response to speciﬁc types of dsRNA11–13,19. Deletion of
MDA5 or MAVS has also been shown to rescue embryonic
lethality in Adar1−/− mice11,12,19. Notably, MDA5 gene expres-
sion and protein levels correlate with ADAR KO-sensitivity across
a spectrum of cancer cell lines (Fig. 1c and Supplementary Fig. 3a,
b). However, deletion of neither MDA5 nor MAVS could rescue
cell lethality after ADAR knockout in the cell lines tested (Fig. 2a,
b and Supplementary Fig. 3c–f), indicating that MDA5/MAVS
signaling is dispensable for this phenotype.
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Consistent with the known role of ADAR1 in suppressing IFN-
β expression12,20, ADAR1-deﬁcient A549 cells secreted increased
amounts of IFN-β in response to IFN-β stimulation (Fig. 2c),
whereas control A549 cells did not. NCI-H1437 cells served as an
additional control in this experiment since this cell line displays
homozygous loss of the IFNB1 gene. Notably, IFN-β treatment
upregulated MDA5 protein levels in A549 cells (Fig. 2d),
suggesting that MDA5 may mediate this phenomenon of
interferon-induced interferon production. Deletion of either
MDA5 or MAVS prior to ADAR knockout abrogated the
interferon-induced interferon production phenotype observed in
ADAR1-deﬁcient A549 cells (Fig. 2e and Supplementary Fig. 3g)
without affecting the cell lethality induced by the combination of
ADAR1 depletion and IFN-β treatment (Fig. 2f and Supplemen-
tary Fig. 3h). Together, these data support the notion that ADAR
knockout can trigger the activation of the IFN-I pathway (MDA5/
MAVS-dependent) and the induction of cell lethality (MDA5/
MAVS-independent) through distinct upstream mechanisms in
cancer cell lines.
Since the MDA5/MAVS cytosolic RNA sensing pathway is not
essential for ADAR genetic dependency, we next examined
whether the cGAS/STING cytosolic DNA sensing pathway may
mediate the cell lethality induced by ADAR1 loss. Indeed, we
observed that ADAR KO-sensitive cell lines produced higher
levels of the adaptor protein STING as compared to ADAR KO-
insensitive cell lines (Supplementary Fig. 4a). Moreover, deletion
of STING in ADAR KO-sensitive HCC366 cells resulted in
decreased protein levels of ISGs such as MDA5 and ISG15
(Supplementary Fig. 4b). However, STING deletion did not
rescue the cell lethality induced by ADAR1 inactivation in
HCC366 cells (Supplementary Fig. 4c), suggesting that the
cytosolic DNA sensing pathway is not essential for ADAR genetic
dependency.
PKR activation mediates cell lethality induced by ADAR1 loss.
As an alternative approach to interrogate the mechanisms
underlying ADAR1 dependency, we performed differential gene
expression analysis between an expanded set of ADAR1-
dependent and non-ADAR1-dependent cancer cell lines of
diverse lineages (Supplementary Data 3)9,18,21. The most statis-
tically signiﬁcant differentially expressed gene in ADAR1-
dependent cell lines was EIF2AK2, which encodes the dsRNA-
activated protein kinase, PKR (Fig. 3a). PKR is an antiviral
cytoplasmic dsRNA sensor with kinase activity. Upon binding of
dsRNA, PKR undergoes dimerization and auto-phosphorylation
at threonine residue 446, which results in its activation14,22.
Activated PKR initiates downstream signals to inhibit protein
translation and induce apoptosis14,23.
Given the high expression of PKR in ADAR1-dependent cell
lines, we hypothesized that PKR may mediate cell lethality after
ADAR deletion. Indeed, we detected increased PKR auto-
phosphorylation at threonine 446 after ADAR knockout in
ADAR1-dependent cell lines (Fig. 3b and Supplementary Fig. 5a).
In ADAR KO-insensitive cell lines (A549 and NCI-H1437), we
observed increased levels of PKR phosphorylation only after the
combination of ADAR1 depletion and IFN-β treatment (Supple-
mentary Fig. 5b). Activated PKR is known to phosphorylate the
eukaryotic translation initiation factor, eIF2α, and lead to
activation of the ATF4 transcription factor24. RNA-seq analysis
conﬁrmed that expression of canonical ATF4-regulated genes,
such as PPP1R15A, ATF3, DDIT3, GADD45A, GADD45B, TRIB3,
and ASNS, were enriched after ADAR knockout in ADAR1-
dependent cell lines (Fig. 3c). Moreover, the combination of
ADAR deletion and IFN-β treatment induced a similar enrich-
ment in the expression of ATF4-regulated genes in the non-
ADAR1-dependent cell line, A549 (Fig. 3c). Together, these data
show that signaling through PKR is activated after ADAR
knockout.
To establish a mechanistic link between PKR and ADAR1
dependency, we deleted PKR in ADAR KO-sensitive HCC366 and
NCI-H1650 cells prior to ADAR deletion (Supplementary Fig. 5c).
Consistent with its known role in promoting apoptosis14, deletion
of PKR partially rescued cell lethality induced by ADAR knockout
(Fig. 3d and Supplementary Fig. 5d), although the magnitude of
this rescue varied between the cell lines tested. Likewise, in
normally ADAR KO-insensitive A549 cells, deletion of PKR
partially rescued the cell lethality triggered by IFN-β treatment in
the context of ADAR1 deﬁciency (Fig. 3e and Supplementary
Fig. 5e). These data demonstrate that the cell lethality induced by
ADAR knockout is mediated at least in part through activation of
PKR signaling.
Catalytically inactive ADAR1-p150 can prevent cell lethality.
ADAR1 could inhibit PKR activation and prevent cell lethality in
cancer cell lines through several distinct mechanisms25,26. Since
dsRNA is a known ligand for PKR, one possibility is that ADAR1
prevents PKR activation by limiting the pool of cytoplasmic
dsRNA through its catalytic deaminase function27,28. Alter-
natively, ADAR1 has been shown to interact directly with PKR
and inhibit PKR activation after viral infection25,26. To differ-
entiate between these possibilities, we ﬁrst engineered different
variants of ADAR1 to be resistant to CRISPR-Cas9-mediated
silencing and overexpressed these variants in ADAR1-dependent
cell lines. While overexpression of the wild-type (WT) p150
isoform of ADAR1 prior to deletion of endogenous ADAR1
prevented PKR phosphorylation and rescued cell lethality, over-
expression of the WT p110 isoform had minimal effects on these
phenotypes (Fig. 4a–c and Supplementary Fig. 6b–f). These data
indicate that the p150 isoform of ADAR1 is critical for inhibiting
Fig. 2 MDA5 and MAVS are required for IFN-induced IFN-β production, but not cell lethality, after ADAR deletion. a, b Cell viability of control and MDA5-
deﬁcient (a) or MAVS-deﬁcient (b) HCC366 cells was assessed by crystal violet staining 8–13 days after GFP or ADAR KO with CRISPR-Cas9. A
representative image of crystal violet staining (top) and quantitation of cell viability (bottom) from two independent biological replicates (for both a and b)
are shown. Cell viability values were normalized to the GFP sg2 control #2 within each group of isogenic cell lines. c IFN-β secretion by control or ADAR1-
deﬁcient A549 cells was measured by ELISA after treatment with either vehicle or IFN-β (10 ng/mL) for 24 h. NCI-H1437 cells harbor a homozygous
deletion of the IFNB1 locus. Technical replicates from one representative experiment are shown. Three independent biological replicates were performed for
A549 cells and one experiment was performed for NCI-H1437 cells. d Immunoblots showing MDA5 and MAVS protein levels in control (GFP sgRNAs) and
ADAR1-deﬁcient A549 cells 24 h after treatment with vehicle or IFN-β (10 ng/mL). β-Actin served as a loading control. One representative immunoblot
from two independent biological replicates is shown. e IFN-β secretion by the indicated A549 cells was measured by ELISA after treatment with vehicle or
IFN-β (10 ng/mL). Technical replicates from one representative experiment out of two independent biological replicates are shown. f Cell viability of the
indicated A549 cells from e was assessed by cell counting 2 days after treatment with vehicle or IFN-β (10 ng/mL). Cell viability values were normalized to
the GFP sg2 control #2 within each group of vehicle or IFN-β-treated isogenic cell lines. Two independent biological replicates are shown. Error bars
represent standard deviation in all graphs
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PKR activation and preventing cell lethality in ADAR1-
dependent cancer cell lines.
To examine whether the catalytic function of ADAR1 is
necessary to prevent PKR activation and subsequent cell lethality,
we generated a previously described catalytically inactive
mutant of ADAR1-p150 (E912A)16,29 (Supplementary Fig. 6a).
Overexpression of E912A ADAR1-p150 inhibited PKR
phosphorylation and rescued cell lethality after ADAR deletion
to a similar degree as WT ADAR1-p150 in HCC366 cells (Fig. 4a,
b and Supplementary Fig. 6b, c, e). We observed similar results in
NCI-H1650 cells, although the degree of rescue observed with
E912A ADAR1-p150 in this cell line was less robust compared
to WT ADAR1-p150 (Fig. 4a, c and Supplementary Fig. 6b, d,
and f). Together, these data suggest that both catalytic and
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non-enzymatic functions of ADAR1 may be important to prevent
cell lethality in a subset of cancer cell lines, although the relative
contribution of each of these functions may be cancer cell line-
speciﬁc.
Discussion
In summary, we have identiﬁed ADAR loss as a genetic depen-
dency in a subset of lung cancer cell lines which possess a high
interferon gene expression signature. Although an elevated
interferon gene expression signature is predictive of ADAR1-
dependence, the mechanisms underlying this sensitivity to ADAR
knockout will require further investigation. The p150 isoform of
ADAR1 appears to prevent lethality in cancer cell lines at least
partly through inhibition of the cytoplasmic RNA sensor PKR
(Fig. 4d). Overexpression studies suggest that both the catalytic
and non-enzymatic functions of ADAR1-p150 may contribute to
limiting PKR activation and preventing cell lethality in ADAR1-
dependent cancer cell lines. Distinct from the cell lethality phe-
notype, loss of ADAR1 primes cancer cell lines to produce IFN-β
in response to IFN-β stimulation in a MDA5/MAVS-dependent
manner (Fig. 4d).
Our data show that MDA5/MAVS signaling is not essential for
ADAR genetic dependency in lung cancer cell lines. These data
are distinct from previously published studies, which demon-
strated a critical role for the MDA5/MAVS pathway in the
embryonic lethality phenotype observed in Adar1−/−mice12,13,19.
Notably, this embryonic lethality results from failure of early
erythropoiesis. One explanation for this difference is that the
downstream pathways that mediate cellular lethality after ADAR
deletion may vary depending on the speciﬁc cell type, develop-
mental stage, and/or malignant nature of the cells under
investigation.
Furthermore, a prior study reported that RNaseL can mediate
cellular lethality after ADAR deletion in A549 cells30. Using these
published sgRNAs to delete ADAR in A549 cells (Supplementary
Fig. 7), we did not observe any signiﬁcant changes in cellular
viability, as evidenced by the fact that we could harvest substantial
amounts of protein from ADAR1-deﬁcient A549 cells after ADAR
knockout. One possible interpretation is that genetic drift of A549
cells passaged in different laboratories may explain these dis-
crepant results31.
ADAR1 represents a unique therapeutic target as loss of its
activity can cause both cell-intrinsic lethality and the induction of
a key anti-tumor cytokine. Inhibition of ADAR1 could directly
kill a subset of cancers that express high levels of ISGs via the
activity of PKR. Furthermore, ADAR1 inhibition might amplify
the IFN-I response in the tumor microenvironment by triggering
IFN-β production by tumor cells. Thus, ADAR1 inhibitors could
synergize with existing cancer immunotherapies through stimu-
lation of cytotoxic T and natural killer cells (J. Ishizuka, R.T.
Manguso, and W.N. Haining, personal communication).
Our study suggests several possible approaches to disrupt the
function of ADAR1 in cancer cells: direct enzymatic inhibition
of its adenosine deaminase activity and/or inactivation of
non-enzymatic functions unique to the p150 isoform, such as
direct PKR binding. Further experiments will be required to
determine the utility of each of these approaches for cancer
therapeutics.
Methods
Cell lines and culture conditions. Cancer cell lines were grown and maintained in
RPMI media supplemented with 10% fetal bovine serum (FBS), and 1% penicillin,
streptomycin, and L-glutamine. The following cancer cell lines were obtained from
the CCLE: A549, NCI-H460, NCI-H1299, NCI-H1437, RERFLCAI, HCC366,
HCC1438, NCI-H196, NCI-H596, NCI-H1650, and SW900 (lung); PATU-8902
(pancreas); RKO (colorectal); AGS (stomach); BT20 (breast); and RKN (soft tis-
sue). Prior to shipping each cell line, the CCLE performed cell line authentication
with DNA ﬁngerprinting and mycoplasma testing.
CRISPR-Cas9 gene knockout. Single guide RNA sequences were designed using
the sgRNA Designer tool on The RNAi Consortium (TRC) portal (http://portals.
broadinstitute.org/gpp/public/analysis-tools/sgrna-design). sgRNA sequences are
displayed in Supplementary Table 2. sgRNAs were cloned into the Cas9-expressing
lentiviral vector CRISPRv2 (http://www.genome-engineering.org/crispr). For len-
tivirus production, individual CRISPRv2 vectors were introduced along with
packaging vectors into 293 T cells via calcium phosphate transfection according to
the manufacturer’s instructions (Clontech). Lentivirus was harvested at 48 and 72 h
after transfection in RPMI media supplemented with 10% FBS and ﬁltered with 45
μm ﬁlters before transduction of cancer cell lines. Transduced cell lines were
selected in 2 μg/mL puromycin and/or 10 μg/mL blasticidin for at least 5 days prior
to use in assays. Thereafter, protein lysates were collected from the transduced cells
and protein levels of the targeted gene(s) were assessed by immunoblotting. For cell
lines in which two genes were knocked out, stable single KO cell lines maintained
under 2 μg/mL puromycin selection were transduced with lentivirus expressing
Cas9, a second guide RNA, and a blasticidin resistance marker. Double KO cells
were selected with both 2 μg/ml puromycin and 10 μg/ml blasticidin for at least
5 days prior to use in assays.
Cell viability assays. Cell counting was performed using a Vi-Cell XR Cell
Counter (Beckman-Coulter). For ATP bioluminescence experiments, cells were
plated at a density of 3000 cells per well in 96-well assay plates (Corning). ATP
bioluminescence was assessed at 3 and 6 days after plating with the CellTiter-Glo
Luminescent Cell Viability Assay (Promega). For crystal violet staining, cells were
plated at a density ranging from 25,000 to 100,000 cells per well in 12-well tissue
culture plates. Once the GFP control cells grew to near conﬂuency, each well was
washed twice with ice cold PBS, ﬁxed with ice cold methanol for 10 min on ice,
stained with 0.5% crystal violet solution (made in 25% methanol) for 10 min at
room temperature, and washed at least four times with water. To quantify cell
viability in crystal violet stained plates, images were obtained from ﬁve ﬁelds of
each well at ×40 magniﬁcation with an Olympus inverted microscope. The number
of cell nuclei in each image was counted using ImageJ and averaged for each well.
All cell viability assays were performed in triplicate.
Antibodies and immunoblotting. Cells were lysed in RIPA lysis buffer (Thermo
Fisher Scientiﬁc) supplemented with 1× protease and phosphatase inhibitor
cocktails (Roche). Protein concentrations were obtained using the BCA Protein
Assay Kit (Pierce) and normalized between all samples. Protein extracts were
analyzed by standard immunoblotting with the following primary antibodies:
ADAR1 (#14175), ISG15 (#2758), MAVS (#3993), MDA5 (#5321), STING
(#13647), total PKR (#3072), and phospho-STAT1 Tyr701 (#9167) from Cell
Fig. 3 Cell lethality after ADAR deletion is partially mediated through activation of PKR signaling. a Analysis of differentially expressed genes between ADAR
KO-sensitive and KO-insensitive cancer cell lines using gene expression data from CCLE17. Differentially expressed genes are plotted by −log(q-value) on
the y-axis versus log2(fold change) on the x-axis. b Immunoblots showing phosphorylated (Thr-446) and total PKR protein levels 5 days after ADAR
deletion by CRISPR-Cas9 for the indicated cell lines (n= 5). β-Actin served as a loading control. c Heat maps showing standardized t-statistics of
normalized expression values for the indicated genes (rows) after deletion of GFP (control) or ADAR (columns) in the indicated cancer cell lines (n= 1).
Color scales show relative normalized expression between ADAR and GFP KO samples. d Cell viability of control or PKR-deﬁcient HCC366 cells was
assessed by crystal violet staining 8 days after GFP or ADAR KO with CRISPR-Cas9. A representative image of crystal violet staining (left) and quantitation
of cell viability (right) from two independent biological replicates are shown. Cell viability values were normalized to the GFP sg2 control #2 within each
group of isogenic cell lines. e Cell viability of control, PKR-deﬁcient, ADAR1-deﬁcient, or ADAR1/PKR double-deﬁcient A549 cells was assessed by ATP
bioluminescence 3 days after treatment with vehicle or IFN-β (10 ng/mL). ATP bioluminescence values were normalized to the vehicle-treated control
within each isogenic cell line. Data from two biological replicates are shown. Note: ADAR sg2 was used in this experiment. Error bars represent standard
deviation in all graphs
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Signaling; phospho-PKR Thr-446 (ab32036) from Abcam; IFNAR1 (A304-290A)
and total STAT1 (A302-752A) from Bethyl; and β-actin (sc-47778) from Santa
Cruz. All antibodies were used at a dilution of 1:1000 except β-actin which was
used at a dilution of 1:4000 or 1:5000. The following secondary antibodies were
used at a 1:5000 or 1:10,000 dilution: Goat anti-Rabbit IRDye 800CW (LI-COR,
926-32211) and Goat anti-Mouse IRDye 680LT (LI-COR, 926-68020) from LI-
COR Biosciences. Immunoblots for phospho-PKR and phospho-STAT1 were
stripped with Restore Western Blot Stripping buffer (Thermo Fisher Scientiﬁc,
#21059) prior to immunoblotting with total PKR and total STAT1, respectively.
Immunoblots were imaged using the LI-COR digital imaging system and ImageJ.
Quantitation of band intensities was performed with ImageJ. All immunoblots
were cropped to optimize clarity and presentation. Uncropped scans of the
immunoblots presented in the main ﬁgures of this manuscript are shown in
Supplementary Fig. 8.
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Enzyme-linked immunosorbent assay. IFN-β detection was performed with the
VeriKine-HS Human IFN Beta Serum ELISA Kit (PBL Assay Science) according to
the manufacturer’s instructions. To detect spontaneous IFN-β production, 4 × 105
cells were seeded in six-well culture plates on day 1. On day 2, the culture media
was replaced with 1.5 mL of fresh media for each well. On day 3, 200 μL of con-
ditioned media from each well was collected and spun to pellet cells. Fifty
microliters of conditioned media was assayed in duplicate for each sample. Fresh
RPMI media was used as the diluent for all standards and blanks. All concentra-
tions of IFN-β were calculated according to the standard curve generated in each
experiment. For exogenous IFN-I treatment experiments, 2 × 105 cells were seeded
in six-well culture plates on day 1. On day 2, the culture media was replaced with
media supplemented with recombinant IFN-α or IFN-β (both at 10 ng/ml). On day
3, the culture media was replaced with 1.5 mL fresh media for each well. On day 4,
the enzyme-linked immunosorbent assay was performed on the conditioned media
as described above.
Interferon treatment. For interferon treatment assays, cells were plated at a
density of 3000 cells per well in a 96-well assay plate (Corning). The following day,
cells were treated with human interferon-alpha 1 (Cell Signaling, #8927) or
recombinant human IFN-beta 1a (mammalian) protein (PBL Assay Science,
#114151). Control wells were treated with sterile water (vehicle). Cell viability was
assayed 3 days after IFN-I treatment with CellTiter-Glo Luminescent Cell Viability
Assay (Promega). The ATP bioluminescence values of the treated wells were
normalized to those of the vehicle-treated controls. Apoptosis was assayed 3 days
after IFN-I treatment with the Caspase-Glo 3/7 Assay (Promega). Dose curves were
obtained using least-squares nonlinear regression on a standard four-parameter
logistic model using GraphPad Prism 7 software.
RNA-sequencing and analysis. For GFP control or ADAR1-deﬁcient A549 cell
lines, cells were treated with 10 ng/mL IFN-β or sterile water (vehicle) for 24 h
before RNA isolation. For HCC366, NCI-H1650, and NCI-H196 cells, RNA was
isolated 5 days after transduction with lentivirus co-expressing Cas9 and sgRNAs
targeting GFP or ADAR. RNA was isolated using the RNeasy Kit (Qiagen) with on-
column DNase I treatment followed by ribosomal RNA depletion using the
NEBNext rRNA Depletion Kit (E6310). RNA sequencing libraries were prepared
using the NEBNext Ultra Directional RNA Library Prep Kit (E7420S) and
sequenced on the Illumina HiSeq instrument (150-bp paired-end reads). Align-
ment against the human genome (hg19) was performed using the STAR aligner32.
Reads were quantiﬁed using HTSeq33 and each gene was then ﬁt with a generalized
linear model using DESeq2 (ref. 34).
Heat maps showing standardized t-statistics (Tij) of normalized expression
values for each sample per gene were calculated using Tij= (xij–xj)/(sj/√n), where
xij= normalized expression value for sample i and gene j, xj= sample mean for
normalized expression of gene j, sj= sample standard deviation for normalized
expression of gene j, n= number of samples.
To generate interferon gene expression signature scores for cancer cell lines in
the CCLE (Supplementary Data 2), a list of 27 ISGs (columns in Supplementary
Data 2) that were signiﬁcantly differentially expressed between ADAR KO-sensitive
and KO-insensitive lung cancer cell lines was compiled from Supplementary
Data 1. Interferon gene expression signature scores were computed by taking the
sum of log2(x+ 1) transformed RPKM expression values across all 27 genes in the
signature. These raw sums were standardized and the z-scores were reported as the
ﬁnal interferon gene expression signature scores for each of the CCLE cell lines
(Supplementary Data 2).
ADAR1 mutagenesis and overexpression. An ADAR open-reading frame (ORF)
clone was obtained from GeneCopoeia (C0744). The entire ORF was sequenced to
conﬁrm ﬁdelity to the NCBI Reference Sequence NM_001111.4. Entry clones for
both ADAR1 p110 and p150 were obtained through PCR-ampliﬁcation of the
ADAR ORF and were sub-cloned into a Gateway donor vector. Using the Quik-
Change Lightning Site-Directed Mutagenesis Kit (Agilent), silent mutations were
introduced separately into the protospacer adjacent motif (PAM) sequences tar-
geted by ADAR sgRNA 1 and sgRNA 2 to render the constructs resistant to
CRISPR-Cas9 editing by these sgRNAs. Subsequently, the E912A mutation was
engineered into each CRISPR-Cas9-resistant ADAR1 construct separately using
site-directed mutagenesis. The resulting CRISPR-Cas9-resistant ADAR1 constructs
and a GFP control construct were sub-cloned into the pLX307 lentiviral expression
vector (Addgene) under the control of an EF-1α promoter. Each expression vector
was then transfected into 293 T cells to generate lentivirus. Lentiviral transduction
of target cell lines was performed as described above.
Statistical analysis. No statistical methods were used to predetermine sample size.
Investigators were not blinded to sample allocation for any of the experiments.
Data in all graphs are presented as the mean of either independent biological or
technical replicates, as indicated in the ﬁgure legends, with all error bars repre-
senting standard deviation. The Krusal–Wallis test was utilized in Fig. 1b. The two-
way ANOVA with Dunnett’s multiple comparisons post-test was utilized for Fig. 1f
and Supplementary Fig. 1c. Pearson’s correlation coefﬁcient (R2) was calculated by
linear regression analysis in Supplementary Fig. 3b. Statistical comparisons of
differential gene expression between groups of ADAR KO-sensitive and KO-
insensitive cell lines were made with Mann–Whitney U tests in Supplementary
Data 1 and 3. p-values less than 0.05 were considered to be statistically signiﬁcant.
All statistical tests were performed using R version 3.4.1 or GraphPad Prism
7 software.
Data availability
The raw and processed RNA-seq data presented in Fig. 3c can be accessed at the
NCBI Gene Expression Omnibus repository (accession code GSE122168). The
authors declare that all other data supporting the ﬁndings of these study are pre-
sented in Supplementary Table 1 and Supplementary Data 1–3. The source data
used to generate Fig. 1a were obtained from publicly available shRNA screening
datasets (Achilles v2.20.2 ExpandedGeneZSolsCleaned.csv) located in the Project
Achilles Data Portal [http://portals.broadinstitute.org/achilles/]9,18. Additional
publicly available ADAR knockdown data were obtained from the Project DRIVE
Data Portal as of 31 August 2017 [https://oncologynibr.shinyapps.io/drive/]21.
Publicly available CRISPR-Cas9 screening datasets (Achilles v3.3.8 Achilles_v3.3.8.
Gs.gct) were also obtained from the Project Achilles Data Portal [http://portals.
broadinstitute.org/achilles/]9,18. RNA-seq gene expression data
(CCLE_RNAseq_081117.rpkm.gct) used to generate Fig. 3a, Supplementary Fig. 3b,
and Supplementary Data 1 through 3 were obtained from the publicly available
CCLE Data Portal [http://www.broadinstitute.org/ccle]17. A reporting summary for
this Article is available as a Supplementary Information ﬁle.
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